JP2008520716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520716A5 JP2008520716A5 JP2007543320A JP2007543320A JP2008520716A5 JP 2008520716 A5 JP2008520716 A5 JP 2008520716A5 JP 2007543320 A JP2007543320 A JP 2007543320A JP 2007543320 A JP2007543320 A JP 2007543320A JP 2008520716 A5 JP2008520716 A5 JP 2008520716A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- formula
- hydrogen
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000037067 skin hydration Effects 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 0 CC(C)[C@@](CC1)[C@@](CCC2)[C@@]1C2=CC=C(C[C@@]1*)C[C@@](*)C1=C Chemical compound CC(C)[C@@](CC1)[C@@](CCC2)[C@@]1C2=CC=C(C[C@@]1*)C[C@@](*)C1=C 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63018204P | 2004-11-22 | 2004-11-22 | |
| US60/630,182 | 2004-11-22 | ||
| PCT/US2005/042030 WO2006057932A2 (en) | 2004-11-22 | 2005-11-18 | 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520716A JP2008520716A (ja) | 2008-06-19 |
| JP2008520716A5 true JP2008520716A5 (enExample) | 2009-01-15 |
| JP5043674B2 JP5043674B2 (ja) | 2012-10-10 |
Family
ID=36215592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543320A Expired - Fee Related JP5043674B2 (ja) | 2004-11-22 | 2005-11-18 | ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7238681B2 (enExample) |
| EP (1) | EP1817278B1 (enExample) |
| JP (1) | JP5043674B2 (enExample) |
| AT (1) | ATE472528T1 (enExample) |
| AU (1) | AU2005309747A1 (enExample) |
| CA (1) | CA2588417C (enExample) |
| DE (1) | DE602005022098D1 (enExample) |
| ES (1) | ES2349662T3 (enExample) |
| MX (1) | MX2007006544A (enExample) |
| NZ (1) | NZ555280A (enExample) |
| WO (1) | WO2006057932A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713951B2 (en) * | 2004-04-09 | 2010-05-11 | Wisconsin Alumni Research Foundation | 2-alkylidene-18,19-dinor-vitamin D compounds |
| JPWO2009116557A1 (ja) * | 2008-03-21 | 2011-07-21 | 富士フイルム株式会社 | 薬剤含有組成物 |
| US20110237557A1 (en) * | 2010-03-23 | 2011-09-29 | Deluca Hector F | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| US8604009B2 (en) * | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
| US8420839B1 (en) | 2011-10-05 | 2013-04-16 | Wisconsin Alumni Research Foundation | Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol |
| EP2746252A1 (en) * | 2012-12-21 | 2014-06-25 | Wisconsin Alumni Research Foundation (WARF) | Crystallization of 1alpha-hydroxy-2-methylene- 18,19-dinor-homopregnacalciferol |
| AU2012268858B2 (en) * | 2012-12-21 | 2017-03-09 | Wisconsin Alumni Research Foundation | Crystallization of 1a-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| AU7544501A (en) | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| ATE346839T1 (de) * | 2002-03-29 | 2006-12-15 | Wisconsin Alumni Res Found | Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| WO2005051323A2 (en) * | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
-
2005
- 2005-11-18 CA CA2588417A patent/CA2588417C/en not_active Expired - Fee Related
- 2005-11-18 WO PCT/US2005/042030 patent/WO2006057932A2/en not_active Ceased
- 2005-11-18 NZ NZ555280A patent/NZ555280A/en not_active IP Right Cessation
- 2005-11-18 MX MX2007006544A patent/MX2007006544A/es active IP Right Grant
- 2005-11-18 AT AT05848578T patent/ATE472528T1/de not_active IP Right Cessation
- 2005-11-18 JP JP2007543320A patent/JP5043674B2/ja not_active Expired - Fee Related
- 2005-11-18 DE DE602005022098T patent/DE602005022098D1/de not_active Expired - Lifetime
- 2005-11-18 US US11/283,222 patent/US7238681B2/en not_active Expired - Lifetime
- 2005-11-18 AU AU2005309747A patent/AU2005309747A1/en not_active Abandoned
- 2005-11-18 ES ES05848578T patent/ES2349662T3/es not_active Expired - Lifetime
- 2005-11-18 EP EP05848578A patent/EP1817278B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520689A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2010505739A5 (enExample) | ||
| JP2008520691A5 (enExample) | ||
| JP2008520705A5 (enExample) | ||
| JP2009532458A5 (enExample) | ||
| JP2010504995A5 (enExample) | ||
| JP2008520716A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2010001302A5 (enExample) | ||
| JP2010514807A5 (enExample) | ||
| WO2006004658A3 (en) | Furanopyrimidines | |
| JP2008520704A5 (enExample) | ||
| JP2008520706A5 (enExample) | ||
| JP2011527699A5 (enExample) | ||
| JP2013506674A5 (enExample) | ||
| JP2008530110A5 (enExample) | ||
| JP2008520690A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2011527696A5 (enExample) | ||
| JP2008520709A5 (enExample) | ||
| CA2588410A1 (en) | 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses | |
| CA2588415A1 (en) | 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses | |
| JP2010504994A5 (enExample) |